This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_IMMUNOPROLIFERATIVE_EXALLC for full statistics.
Malignant immunoproliferative diseases
CD2_IMMUNOPROLIFERATIVE
lymphoma: A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
232
Check minimum number of events None
232
Include endpoints None
232
Remove individuals based on genotype QC
223
CD2_IMMUNOPROLIFERATIVE
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF4
Parent code in ICD-10
C81-C96
Name in latin
Morbi immunoproliferativi maligni
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Malignant immunoproliferative diseases
based on the number of shared cases.
Broader endpoints:
- Malignant immunoproliferative diseases (controls excluding all cancers)
- Primary_lymphoid and hematopoietic malignant neoplasms
- Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers)
- Malignant neoplasm
- Malignant neoplasm (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 223 | 94 | 129 |
| Unadjusted prevalence (%) | 0.06 | 0.04 | 0.08 |
| Mean age at first event (years) | 66.43 | 64.81 | 67.61 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_IMMUNOPROLIFERATIVE – Malignant immunoproliferative diseases
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Malignant immunoproliferative diseases
↥Endpoint not on priority list, no data to show.